Labetuzumab I-131

Drug Profile

Labetuzumab I-131

Alternative Names: Anti-CEA monoclonal antibody MN 14-I-131; CEA-Cide-I-131; hAFP-Y-90; Humanised anti-CEA monoclonal antibody MN 14-I-131; IMMU-111

Latest Information Update: 26 Aug 2015

Price : $50

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals; Radiosensitisers
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Colorectal cancer
  • Discontinued Liver cancer; Thyroid cancer

Most Recent Events

  • 03 Jun 2008 Efficacy and adverse events data from a phase II trial in colorectal liver metastases presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 04 Jun 2007 Interim results from a phase II clinical trial in patients with resected liver metastases from primary colorectal cancer added to the adverse events and Cancer therapeutic trials sections
  • 19 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top